JERUSALEM, Apr 20, 2012 (BUSINESS WIRE) --Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that
it will release its first quarter 2012 financial results on Wednesday,
May 9, 2012.
Teva will host a conference call and live webcast on the same day, at
8:30 a.m. ET to discuss its first quarter 2012 results and overall
business environment. A Question & Answer session will follow this
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States and Canada
1-866-652-8972; International 972-3-918-0687; Israel 1-800-227-297 and
the United Kingdom 00-800-032-3367.
A live webcast of the call will also be available on Teva's website at: www.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until May 16, 2012, at 11:59 p.m. ET by calling
1-877-456-0009 or 972-3-925-5921.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
largest generic drug maker, with a global product portfolio of more than
1,300 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $18.3 billion
in net revenues in 2011.
SOURCE: Teva Pharmaceutical Industries Ltd.
Kevin C. Mannix,
Tomer Amitai, 972 (3) 926-7656
Denise Bradley, (215) 591-8974
Altay-Hagoel, 972 (3) 926-7590